Serious Fraud Office Investigation

GlaxoSmithKline plc (LSE/NYSE: GSK) has today been informed by the UK’s Serious Fraud Office (SFO) that it has opened a formal criminal investigation into the Group’s commercial practices.
Source: GSK news - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals